The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies
Open Access
- 28 October 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Blood Cancer Journal
- Vol. 1 (10), e41
- https://doi.org/10.1038/bcj.2011.42
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantationBlood, 2011
- Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European PerspectiveThe Oncologist, 2011
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological TumorsThe Journal of Immunology, 2011
- State of the art treatment of chronic lymphocytic leukaemiaBlood Reviews, 2011
- Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumabHaematologica, 2010
- Phase II Trial of Lenalidomide - Dexamethasone - Rituximab In Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to RituximabBlood, 2010
- Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel AgentsJournal of Clinical Oncology, 2010
- Recent major improvement in long-term survival of younger patients with multiple myelomaBlood, 2008
- Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to ProgressionJournal of Clinical Oncology, 2007